Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and PDT in Metastatic ESCC
NCT05386056Phase 2Unknown
- Sponsor
- Peking University
- Start
- Dec 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cosiporfin sodium in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking University. Primary endpoint: Objective Response Rate up to 2 years. Status: unknown.
02
Drugs
cosiporfin sodium
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05386056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05386056.